Thursday, November 4^th

Incorporating amyloid imaging in current and/or future collaborative research studies
C.Clark, University of Pennsylvania, USA

Re-thinking Alzheimer Disease therapy; lessons learned from ongoing clinical trials
B. Winblad, KI-Alzheimer Disease Research Center (KI-ADRC), Sweden

Results of the VITACOG trial of homocysteine-lowering B vitamins in subjects with MCI
D.Smith, University of Oxford, U.K, H.Refsum, University of Oslo, Norway

Presymptomatic Tests for AD and the Search for Mechanism
M.J.de Leon et al, New York University Medical Center, USA

Coffee Break and poster session

Designing secondary Preventive trials
P.Aisen, University of Southern California, USA

First results of the PERFORM-Dementia Study : 3-year Incident Dementia
in 19 000 post-stroke patients
J.M.Orgogozo et al, CHU Bordeaux, France

GUIDAGE : Results from the guidage Study
B.Vellas, CHU Toulouse, France

Lunch Break

PANEL DISCUSSION : Stratification of AD patients and inclusion of CSF biomarkers in clinical trials

1. Subgroups of AD based on Clinical and imaging findings
   P.Scheltens, VU University Medical Center, The Netherlands
2. CSF biomarkers for diagnosis and monitoring
   K.Blennow, Sahlgren’s University Hospital, Sweden
3. Different etiopathogenic mechanisms and subgroups of AD based on CSF molecular markers
   K.Iqbal, NY State Institute for Basic Research In Developmental Disabilities, USA
4. Why most AD clinical trials fail?
   P.Aisen, University of Southern California, USA
5. Cost analysis of using pure AD patients versus AD with mixed pathologues in clinical trials
   B.Winblad, KASPAC University, Sweden
6. Stratify or not stratify
   Speaker TBD

1^st Symposium :

Simulating Clinical Trials for AD and MCI
(in order to design them better)

• Overview
  L.Schneider, University of Southern California, USA
  
• Model-based AD drug development and clinical trials: key concepts and examples from early and late development
  B.Corrigan, Pfizer, USA
  
• Understanding the placebo response in AD clinical trials
  K.Ito, Pfizer, USA
  
• Simulations of prodromal AD (aMCI) trials to determine the effect of CSF amyloid-beta42 biomarkers on efficiency and clinical outcomes
  L.Schneider
  and Discussant, H.Hampel, University of Munich, Germany

Lunch Break

2^nd Symposium :

«A Standardized Re-Assessment of Cognitive Instrumentation Used in Clinical Trials for MCI»

• The PAD2020 Survey of Cognitive Instrumentation Used in Clinical Trials for MCI & Prodromal AD
  P.J.Snyder, Warren Alpert Medical School of Brown University, USA
• Developing the ADAS-Cog to enhance its measurement performance for clinical trials of MCI
  J.Hobart, Derifford Hospital, UK
• How, When and Why to Develop a New Generation of Cognitive Instruments for Clinical Trials
  Y.Stern, Columbia University, USA
• Round-Table Panel Discussion
  P.J.Snyder, Y.Stern, P.Maruff, K.Wesnes, J.Hobart

3^rd Symposium :

Clinical trials for Secondary prevention of AD: What is the current evidence

• Methodological issues
• Target population
• Outcome parameters
• Biometrical issues
• G.Biloba - Estrogens - NSAIDs

      Co-chaired by : L.Frölich, CIMH Mannheim, Germany, I.Heuser, Humboldt University, Germany